Phase I trial of intravenous L-phenylalanine mustard plus the sensitizer misonidazole
摘要：
Misonidazole (MISO), a hypoxic cell radiosensitizer, has been shown to enhance tumor cell killing by melphalan (LPAM) with little or no enhancement of normal tissue injury. A Phase I trial was conducted using MISO p.o. 2 hr before i.v. LPAM. The highest doses used were the single maximum tolerated doses of MISO, 4 g/sq m, and LPAM, 0.6 mg/kg. Thirty-five patients were entered; 30 were evaluable for assessment of hematological toxicity, which was predicted to be the dose-limiting toxicity. The median age was 60 years (range, 28 to 72 years). Mild to moderate nausea and vomiting occurred in 80% of patients. Five developed serious hematological toxicity defined as nadir white blood cell count < 1000/cu mm, platelets < 20,000/cu mm or 4-week posttreatment white blood cell count < 2000/cu mm, platelets < 50,000/cu mm. Four of the toxicities occurred at the LPAM dose of 0.6 mg/kg but were independent of MISO dose. One patient died of infection. Two patients whose tumor demonstrated an objective response to therapy and 10 others with disease stabilization received additional courses. Four patients developed mild MISO neuropathy. Pharmacokinetic studies demonstrated that MISO did not appear to affect the pharmacokinetics of LPAM in plasma. Both LPAM and MISO can be given safely at their individual maximum tolerated dose. This combination will proceed to Phase II trials.
展开
DOI：
doi:http://dx.doi.org/
被引量：
年份：
1983
万方医学
Semantic Scholar
(全网免费下载)
NCBI
AACR
AACR
(全网免费下载)
查看更多
AACR
(全网免费下载)
ResearchGate
ResearchGate
(全网免费下载)
mendeley.com
mysciencework.com
通过文献互助平台发起求助，成功后即可免费获取论文全文。
相似文献
参考文献
引证文献
辅助模式
引用
文献可以批量引用啦~
欢迎点我试用！
